AU2021267213B2 - Pharmaceutical combination comprising TNO155 and nazartinib - Google Patents

Pharmaceutical combination comprising TNO155 and nazartinib Download PDF

Info

Publication number
AU2021267213B2
AU2021267213B2 AU2021267213A AU2021267213A AU2021267213B2 AU 2021267213 B2 AU2021267213 B2 AU 2021267213B2 AU 2021267213 A AU2021267213 A AU 2021267213A AU 2021267213 A AU2021267213 A AU 2021267213A AU 2021267213 B2 AU2021267213 B2 AU 2021267213B2
Authority
AU
Australia
Prior art keywords
egfr
per day
amino
tno155
nazartinib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021267213A
Other languages
English (en)
Other versions
AU2021267213A1 (en
Inventor
Huaixiang Hao
Chen Liu
Susan E. MOODY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2021267213A1 publication Critical patent/AU2021267213A1/en
Application granted granted Critical
Publication of AU2021267213B2 publication Critical patent/AU2021267213B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2021267213A 2020-05-08 2021-05-06 Pharmaceutical combination comprising TNO155 and nazartinib Active AU2021267213B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063021772P 2020-05-08 2020-05-08
US63/021,772 2020-05-08
US202063117388P 2020-11-23 2020-11-23
US63/117,388 2020-11-23
PCT/IB2021/053867 WO2021224867A1 (en) 2020-05-08 2021-05-06 Pharmaceutical combination comprising tno155 and nazartinib

Publications (2)

Publication Number Publication Date
AU2021267213A1 AU2021267213A1 (en) 2022-11-03
AU2021267213B2 true AU2021267213B2 (en) 2023-11-30

Family

ID=75904981

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021267213A Active AU2021267213B2 (en) 2020-05-08 2021-05-06 Pharmaceutical combination comprising TNO155 and nazartinib

Country Status (12)

Country Link
US (1) US20230172928A1 (cg-RX-API-DMAC7.html)
EP (1) EP4146217A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023524789A (cg-RX-API-DMAC7.html)
KR (1) KR20230008719A (cg-RX-API-DMAC7.html)
CN (1) CN115397421A (cg-RX-API-DMAC7.html)
AU (1) AU2021267213B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022022305A2 (cg-RX-API-DMAC7.html)
CA (1) CA3179994A1 (cg-RX-API-DMAC7.html)
IL (1) IL297043A (cg-RX-API-DMAC7.html)
MX (1) MX2022013867A (cg-RX-API-DMAC7.html)
TW (1) TW202207933A (cg-RX-API-DMAC7.html)
WO (1) WO2021224867A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL304526B2 (en) 2018-09-29 2025-05-01 Novartis Ag Production of compounds and preparations for inhibiting the activity of SHP2
EP3856345A1 (en) 2018-09-29 2021-08-04 Novartis AG Process of manufacture of a compound for inhibiting the activity of shp2
ES3040751T3 (en) 2020-07-08 2025-11-04 Novartis Ag Manufacture of compounds and compositions for inhibiting the activity of shp2
AU2022341107A1 (en) 2021-09-08 2024-02-29 Amgen Inc. Sotorasib and an egfr antibody for treating cancer comprising a kras g12c mutation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018130928A1 (en) * 2017-01-10 2018-07-19 Novartis Ag Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3300B1 (ar) 2012-06-06 2018-09-16 Novartis Ag مركبات وتركيبات لتعديل نشاط egfr
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
EP3856345A1 (en) * 2018-09-29 2021-08-04 Novartis AG Process of manufacture of a compound for inhibiting the activity of shp2

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018130928A1 (en) * 2017-01-10 2018-07-19 Novartis Ag Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HAO HUAIXIANG ET AL: Abstract LB-122, BIOINFORMATICS, CONVERGENCE SCIENCE, AND SYSTEMS BIOLOGY &AACR ANNUAL MEETING 2020, 22 June 2020, pages B - 122, DOI: 10.1158/1538-7445.AM2020-LB-122 *
TAN DANIEL S-W ET AL: "Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma", THE LANCET. RESPIRATORY MEDICINE, vol. 8, no. 6, 15 January 2020, pages 561-572, DOI: 10.1016/S2213-2600(19)30267-X *

Also Published As

Publication number Publication date
IL297043A (en) 2022-12-01
TW202207933A (zh) 2022-03-01
JP2023524789A (ja) 2023-06-13
AU2021267213A1 (en) 2022-11-03
CN115397421A (zh) 2022-11-25
WO2021224867A1 (en) 2021-11-11
US20230172928A1 (en) 2023-06-08
KR20230008719A (ko) 2023-01-16
BR112022022305A2 (pt) 2022-12-20
EP4146217A1 (en) 2023-03-15
CA3179994A1 (en) 2021-11-11
MX2022013867A (es) 2022-11-30

Similar Documents

Publication Publication Date Title
US12343344B2 (en) Pharmaceutical combination comprising TNO155 and ribociclib
JP7572958B2 (ja) Tno155及びkrasg12c阻害剤を含む医薬組合せ
US20230090389A1 (en) A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a shp2 inhibitor
AU2020222295A1 (en) Pharmaceutical combination comprising TNO155 and a PD-1 inhibitor
US20230172928A1 (en) Pharmaceutical combination comprising tno155 and nazartinib
IL255189B1 (en) A combination of rad1901 and a cdk4/6 inhibitor for use in treating cancer
US20240238284A1 (en) Compounds and compositions for the treatment of mpnst
CA3037456C (en) Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
HK40060474A (en) Pharmaceutical combination comprising tno155 and ribociclib

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)